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Nanotechnology, the technology that brings the atom-by-atom manipulation of matter 
within reach, holds the promise of many societal benefits, such as dramatic progress in 
healthcare, environmental benefits and further advances in computing. Patents will be of 
crucial importance if innovation in nanotechnology is to live up to the expectations 
placed upon it. However, questions can be raised with the large number of patents 
granted for nanotechnology and the basic character of some of these patents. 
Impenetrable patent thickets or patents with great blocking power may be created right 
now. This chapter investigates whether patent law is being applied adequately with a 
view to realising the full innovative potential of nanotechnology and its societal benefits. 
It will not deal with the question of whether nanotechnology is patentable per se, but will 
focus on the way in which patents are currently being granted.  
1  Introduction 
 
Nanotechnology is the technology of the smallest objects. It holds the promise of 
manipulation on an atom-by-atom basis and represents the ultimate control over matter. 
The European Patent Office (hereinafter: EPO) defines nanotechnology as follows 
(Kallinger 2007):  
“The term nanotechnology covers entities with a controlled geometrical size of at 
least one functional component below 100 nanometres in one or more 
dimensions susceptible of making physical, chemical or biological effects 
available which are intrinsic to that size. It covers equipment and methods for 
controlled analysis, manipulation, processing, fabrication or measurement with a 
precision below 100 nanometres.”  
Potentially great societal benefits are in the offing. In healthcare, nanotechnology could 
bring advances such as selected targeting of cancer cells or clean drinking water in 
developing countries. For the environment, nanotechnology could bring benefits such as 
fuel saving additives, more efficient production of solar cells, cleaner generation of 
hydrogen, quickly rechargeable batteries and better insulation of buildings (Walsh 2007). 
In computing nanotechnology brings even smaller chips than the current ones with more 
memory capacity. It is expected that many new products can be developed on the basis 
of nanotechnology and the quality of existing products may be vastly improved (Pen 
2009). However, the benefits of nanotechnology will only materialise if laboratory results 
can be adequately translated into innovations, so that new products and services are 
placed on the market. Patents traditionally play an important role in stimulating 
innovation. There is no doubt that inventions in the field of nanotechnology can be 
protected by patents (Bowman 2007, Newberger 2003). However, certain developments 
indicate that we may not be using patent law in a way that extracts the most from the 
innovative potential that nanotechnology offers. In literature concerns have been voiced 
that patents are being granted on building blocks of the technology, such as relatively 
simple molecules (Lemley 2005, Zekos 2006). If these concerns are justified, some 
patents in nanotechnology would be very valuable, but they would also have an 
enormous potential to block. The same holds for patents on the underlying principles of 
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nanotechnology. They would afford too much power to pioneering innovators and 
upstream researchers. The eagerness to patent nanotechnology also raises concerns 
about the number of patents. Using its wide definition of nanotechnology, the EPO 
identified about 108,000 patent documents relating to inventions in the field of 
nanotechnology (Kallinger 2007). The existence of many patents in the field of 
nanotechnology could hamper downstream innovation. These concerns are as of yet not 
empirically validated. This chapter will however show that nanotechnology possesses a 
number of characteristics that give credence to the concerns raised. Although that does 
not amount to proof of a problem, it will be argued that there is a definite risk that the 
concerns prove to be justified. This chapter further argues that the risk is serious enough 
to consider certain intra-systemic steps to make the patent system function better, so 
that some barriers to innovation in the field of nanotechnology are taken away and 
society is better placed to reap the fruits of nanotechnology. Where possible analogies 
with biotechnology are drawn. Biotechnology has seen a relatively recent scientific and 
technological growth and it experienced to a large extent the same problems with 
respect to patents that nanotechnology faces now. 
The outline of the chapter is as follows. The second section shows in what respects 
nanotechnology differs from existing technologies and what adverse implications this 
may have for innovation. In the third section a number of avenues for addressing the 
issues mentioned in the second section are identified. 
2 The uneasy relation between nanotechnology and the 
patent system 
 
The patent system is designed to spur innovation. Nanotechnology has however some 
characteristics that hinder the patent system in stimulating innovation. I will consider 
here three characteristics in particular. In the first place nanotechnology is science 
based. Secondly, it is interdisciplinary and finally it crosses the borders of industries. I 
will first deal with the scientific nature of nanotechnology.  
2.1 The scientific nature of nanotechnology 
 
The scientific character of nanotechnology has a number of implications for the 
application of patent law. Some of these implications nanotechnology shares with 
biotechnology that also was and is very much science based. I discern the following 
implications: universities are relatively over represented amongst the patentees. What is 
patented may lie close to results of fundamental research. The ensuing patents may 
have great blocking power. The transfer into marketable products often still requires non-
obvious steps. The patentability of inventions can only be adequately ascertained by 
somebody having good knowledge of the academic discussion and literature in the field 
of nanotechnology. Hereinafter, I will elaborate these implications of the science based 
character of nanotechnology  
Nanotechnology is a technology that is still very much the subject of fundamental 
research, much of which is performed by universities and research-institutes. In Europe, 
two thirds of the research into nanotechnology is publicly funded, compared to only 45% 
in the US (Hullmann 2006, p. 15). This relatively low percentage can be attributed to the 
huge private investment in the US in nanotech research. Both in the US and Europe 
many public funds are spent on nanotech research. Universities appear to be particularly 
avid patentees. They are also in a relatively strong position when negotiating licenses on 
their patent portfolio. Since they are not in the business of manufacturing goods their 
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need to obtain licenses from other patentees are relatively low. That makes them much 
less vulnerable for an accusation of patent infringement and that in turn gives them 
leeway when negotiating the conditions for licenses on their own patent portfolio (Lemley 
2008). In reality things are of course a bit more complicated than described here 
(Shrestha 2010, Zvoko 2006). Universities may feel that it is their moral duty to make 
sure that their research results find wide application in society and this may ring through 
in their licensing policies. Universities are also for other than patent reasons dependent 
upon commercial companies. They will want to maintain good relations with commercial 
companies for purposes, such as contract research and access to expensive equipment. 
This circumstance may also make for a more balanced situation in negotiation room. 
Nevertheless, there will be great differences between the licensing policies of 
universities and for a university not each company may be as important as those with 
which it maintains close ties. These multifaceted situations will translate in a wide variety 
of constellations for license negotiations. Therefore, licenses on patents held by 
universities may not always be as easy to obtain as may be thought in first instance. 
Since research with respect to nanotechnology is to a large extent performed by 
universities, much of it bears a fundamental character. Basic ideas, substances and 
processes are being developed. Just as with biotechnology, fears exist that the building 
blocks of the technology will end up being patented. In biotechnology, upstream 
research results, such as DNA sequences, were patented while being far removed from 
a product or service that could readily be offered on the market (Rai 1999 and Rai 
1999a). Such patents may hinder further research (Kane 2006). They merely seem to 
reserve a certain research field for a patentee. According to US patent law expert 
Lemley, it is likely that similar risks are present in the field of nanotechnology (Lemley 
2005). In other technical fields, such as computers, software, the internet, and – 
surprisingly - biotechnology, Lemley observes that patenting started only after 
development of the technology was in full swing. In nanotechnology, patents were 
granted directly from the start of the scientific development. As a consequence, in the 
nanotech industry patents on the basic ideas – the building blocks - of the technology 
would be more prevalent. This could burden downstream innovators as it is practically 
impossible to invent around basic ideas and elements of a discipline. It is hard to assess 
exactly to what extent this problem materialises in nanotechnology. Such assessment is 
further hampered by the fact that nanotechnology is not one homogeneous technology. 
It is a collection of several sciences and technologies that have a small size in common. 
The situation of the various nanomaterial platforms – basic molecules - can be very 
different.  Examples of nanomaterial platforms are inter alia carbon nanotubes 
(hereinafter: CNTs), buckyballs or fullerenes and quantum dots. From platform to 
platform there are differences between the density of the patent landscape and the 
degree in which patents are entangled. This becomes all too evident when comparing 
the patent landscapes for buckyballs and carbon nanotubes. There are no broad patents 
claiming buckyballs per se (Lemley 2005, p.614). A reason may be that buckyballs 
spontaneously occur in nature (Gerhardt et. al. 1987) and therefore may be 
unpatentable discoveries. At the same time, carbon nanotubes per se are being claimed 
in a number of patents. Three patents are often mentioned because of their broad 
scope: US5747161 a patent of NEC, US5424054 a patent of IBM and US6683783, a 
patent of Carbon Nanotechnologies (Lemley 2005 and Harris & Bawa 2007). A fourth 
patent should be mentioned in this respect as well: US4663230, a patent of Hyperion. 
The latter patent concerns a composition of matter using carbon nanotubes. Its first 
claim reads:  
An essentially cylindrical discrete carbon fibril characterized by a substantially 
constant diameter between about 3.5 and about 70 nanometers, length greater 
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than about 102 times the diameter, an outer region of multiple essentially 
continuous layers of ordered carbon atoms and a distinct inner core region, each 
of the layers and core disposed substantially concentrically about the cylindrical 
axis of the fibril. 
This is a broad claim and applications using carbon nanotubes must closely guard that 
they do not infringe this patent. A patent application for the invention has also been filed 
in Europe (EP0205556). The European patent‟s first claim is however narrowed down by 
the inclusion of an extra qualification: ‟said fibril is substantially free from pyrolytically 
deposited thermal carbon‟. In Europe, a purer form is claimed, but even though it 
remains a rather broad patent. In conclusion, when considering carbon nanotubes and 
buckyballs as building blocks, it appears that the former are the object of broad patent 
claims whereas the latter not or at least much less so. 
 It could be asked whether these differences have predictive value for the level of 
innovation. Starting from traditional concerns about the effects of patents on building 
blocks, one would expect that innovation in carbon nanotubes would suffer. However the 
opposite seems to be the case. When looking at the number of patent applications, it 
appears that there are five times as many applications for CNTs than there are for 
buckyballs (Michalitsch et. al. 2008, p. 86). The buckyball patent landscape also shows 
many abandoned patents (Lux Research 2005). These patent based indications are in 
accordance with the trend signalled in literature: expectations for carbon nanotubes are 
high (Harris & Bawa 2007). Buckyballs have disappointed in not living up to the high 
expectations that were placed upon them when they were first discovered (Michalitsch 
et. al. 2008, p. 86, Ball 2005).  
So perhaps the potential for technical and commercial success are more 
important indicators for innovation than the existence of patents on building blocks. That 
does however not take away that innovation might have been higher if patents on 
building blocks would not have existed in the first place. The building block patents may 
very well create uncertainty, because it may be unclear whether innovative activities are 
covered by the patents and if so, it may be unclear whether the patents are valid. 
Especially the uncertainty may have adverse effects on innovation. Concerns about 
patents on building blocks can therefore not be discarded and may need to be 
addressed. 
 The building blocks of nanotechnology must ultimately lead to concrete products 
and services so that the great expectations about the benefits that nanotechnology can 
yield are met. Yet, it has hitherto proven difficult to translate theoretical results into 
marketable products. Only a few products have appeared on the market. In this respect, 
Europe is lagging behind the US (European Commission 2004, p. 7). This may indicate 
that patents are being granted on inventions that have no or at least a very thin industrial 
applicability. This reinforces the fear expressed above that patents may be granted on 
basic ideas in nanotechnology. 
According to research by Meyer, nano-patents tend to cite only other patents and 
to a much smaller degree scientific research papers (Meyer 2001, p. 298). This is 
remarkable in view of the fact that nanotechnology is very much a science based 
discipline. This raises the question whether relevant prior art escapes the patent 
examiners‟ attention. If this is the case, patents are being granted on invention that are 
not novel or lack inventiveness. 




Above it was shown that the scientific character of nanotechnology sits uneasily 
with the patent system. This section investigates how the patent system relates to the 
interdisciplinary and cross-industry character of nanotechnology. The former will be dealt 
with first. The manipulation of matter on the nanometer level is not the prerogative of one 
single technological discipline. Nanotechnology is thoroughly interdisciplinary and its 
applications often are the result of a convergence of pre-existing technologies. 
Disciplines involved in nanotechnology are, inter alia, chemistry, physics, biology, and 
electronics. The interdisciplinary character may mean that nanotech patent applications 
sometimes end up with examiners having expertise X while other similar applications 
end up with examiners having expertise Y. The divisions between examiners with 
different expertises holds a certain risk for overlooking prior art.1 Also the lack of a 
uniform terminology in nanotechnology may magnify the risk of prior art remaining 
undetected. Biotechnology has not or to a much lesser extent been burdened by these 
problems. Therefore, from the interdisciplinary nature of nanotechnology, a certain risk 
of patents being granted for inventions that are not novel or inventive can theoretically 
be deduced. Such a theoretical risk does not amount to empirical evidence supporting a 
claim of overpatenting. Empirical evidence is sparse (Featherstone and Specht 2004). 
The EPO and the organisation on Economic Cooperation and Development (hereinafter 
„OECD‟) are working on monitoring instruments for nanotechnology patents (Hullmann & 
Frycek 2007, p.11-12). These may begin to enlighten us on the empirical aspects of 
patenting in the field of nanotechnology. Even in the absence of empirical evidence, the 
the theoretical reflections about the interdisciplinary character of nanotechnology point to 
deficiencies that may need to be addressed. 
Apart from crossing the boundaries of scientific disciplines, nanotechnology also 
crossed the boundaries of industries. The cross industry character is mainly important 
for the manufacturing stage of nanotechnology. It may expose innovators to a greater 
risk of being accused of patent infringement (Khanijou 2007). On the one hand, this is 
due to patentees from other industrial sectors who may feel less inhibited to enforce their 
patents against innovators outside their own industrial sector. On the other hand, this 
problem is exacerbated by the added complexity of compliance checking. A company 
becoming active in the field of nanotechnology cannot limit its compliance checks to the 
industrial sector in which it is active. A company will need to check patents in other 
industries as well since these patents may read on its activities. Given the size of patent 
databases, the search for relevant patents may amount to gigantean task. In this 
respect, the patent landscape of nanotechnology is more complex than is the case with 
biotechnology, where the number of industries involved is very limited. In view of the fact 
that most nanotechnology products and services have not yet reached the market and 
yet relatively little money is made with nanotechnology, the extent of the problem may 
not yet be visible in its entirety.  
 
3 Addressing the friction between nanotechnology and the 
patent system 
 
Above we have seen that there are multiple reasons for fearing that frictions between 
nanotechnology and the patent system prevent the former from realising its full potential. 
Hereinafter, a number of avenues are investigated for redressing this situation. 
3.1 Person skilled in the art 
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In patent law, a fictional person skilled in the art is used as a criterion figure. For 
example, when assessing the inventiveness of an invention it can be asked according to 
whom the invention needs to be inventive. Technical teachings that a layman finds 
inventive, an expert in the field may find obvious. Patent law solves the issue by 
requiring that an invention is inventive from the perspective of a person skilled in the art. 
This person skilled in the art is usually defined as a person working in the technological 
field in which the invention falls and he is considered to have average knowledge and 
abilities. By choosing the person skilled in the art as a criterion figure, the patentability 
requirement of inventiveness is made more objective. Apart from the requirement of 
inventiveness, there are other requirements that a patent must meet and for which the 
criterion figure is relevant. An invention must for example also be sufficiently disclosed in 
the patent. This means that it must be possible to rework the invention based on the 
information provided in the patent. Here again, the question can be asked who should be 
able to rework the invention. Here too, the issue is resolved by choosing the person 
skilled in the art as the standard by which to measure whether the requirement has been 
met. 
The definition of the person skilled in the art is highly relevant for the 
determination of novelty, inventive step and sufficiency of disclosure in nanotechnology. 
If the person skilled in the art is taken to be highly qualified it is more difficult to meet the 
inventive step requirement, but the disclosure of the invention can be somewhat less 
encompassing. The person skilled in the art can be assumed to be more adept in 
applying the technical teaching of the patent. The opposite also holds: defining the 
person skilled in the art as less highly qualified, makes it easier to meet the inventive 
step hurdle, but obliges a more encompassing enabling disclosure. In a new field, such 
as nanotechnology, it is unclear how the person skilled in the art of nanotechnology is to 
be defined. 
The interdisciplinary character of nanotechnology has a bearing on the definition 
of person skilled in the art of nanotechnology. For example, the interdisciplinary 
character may mean that the person skilled in the art should be a master of many 
disciplines. This leaves open the question what disciplines he should master. The 
function of the concept points the way: with the help of the fictitious person skilled in the 
art, it must be possible to determine what activity would be considered normal progress 
in the art and what would be considered to be a major step in the pertinent technology. 
So, the person skilled in art should reflect the realities in the relevant industry, in this 
case, the pertinent branch in the nanotech industry. This indeed means that 
multidisciplinary talents must be attributed to the person skilled in the art. Apart from the 
abstract question of how to define the person skilled in the art, there is the practical 
issue that the concrete capabilities of patent examiners may rub off on their perception 
of the person skilled in the art. In other words, the monodisciplinary restrictions in the 
capabilities of examiners may influence their perception of the person skilled in the art. 
Thus, a tendency towards a lightly qualified person skilled in the art may result, where 
even the lightness of qualification may be different between patent examiners. An 
examiner may be more inclined to view aspects of an invention as inventive if they are in 
technology domains with which he is less familiar. Being less adept in reading a patent 
in such technology domains an examiner may also require a further elaborated 
disclosure. This effectively comes down to having a less highly qualified person skilled in 
the art as the criterion. It could be objected that it is not the patent examiner, but the 
courts that have the last say on what constitutes a man skilled in the art. Nevertheless, 
the determinations of a patent examiner are relevant, since most patents are never 
litigated. Nanotechnology litigation is still sparse compared to litigation in other domains. 
It will probably only begin to increase when products incorporating nanotechnology are 
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placed on the market on a large scale. Where patents are litigated the patent examiner 
sets the scene for the judgements of the court. For the time being there may be variation 
in the actual standards used in nanotechnology patenting. 
Patent applicants may try to use the interdisciplinary character of nanotechnology 
to their own advantage by engaging in what I call „technology shopping‟. A nanotech 
patent may e.g. concern biological switch. The invention could be dealt with as an 
electronics invention, but alternatively as a biotechnological invention. By adequately 
formulating the claims in terms of a certain „participating‟ discipline the patent applicant 
may try to steer the patent examiner away from relevant prior art. In the same way, it 
may also be possible to select the standards applicable to the determination of the 
person skilled in the art, and in its wake, novelty, inventive step or sufficiency of 
disclosure, since those differ to a larger or smaller extent between disciplines. For 
inventions in the field of biotechnology, research is usually done by postdoctoral 
researchers. The person skilled in biotechnology is accordingly more highly qualified 
than in most other arts (Hacon & Pagenberg 2008, p. 51). At the same time, 
biotechnology apparently is qualified as more uncertain science, where a person skilled 
in the art can not as easily as in other sciences assume the presence of fixed patterns. 
This reflects on the definition of the person skilled in the art. The Technical Board of 
Appeal has defined the person skilled in the art of biotechnology as follows (T 0387/94, 
Max-Planck-Gesellschaft/Monsanto): „His/Her attitude is considered to be conservative. 
"He/She would never go against an established prejudice, nor try to enter unpredictable 
areas nor take uncalculable risks".‟ If an invention lends itself to a choice of art, a patent 
attorney may be able to select a favourable base discipline. By framing the invention in a 
suitable way, he can thus choose the standard applicable to his invention. 
A team approach to a person skilled in the art may solve some of the inherent 
problems associated with the interdisciplinary nature of nanotech inventions. Dependent 
upon the implementation of a team approach there are different effects. The selection of 
an implementation therefore calls for a balancing of the effects. One of the 
implementation decisions to be made involves the qualification of the team skilled in the 
art which may be chosen higher or lower. If the imaginary team is chosen to be a very 
well qualified team this may raise the bar of inventiveness for nanotech inventions and 
may make the disclosures difficult to comprehend for any individual trying to make sense 
of a nanotechnology patent. After all, the drafter of the patent (probably a real life team) 
may presuppose all the knowledge available in the imaginary team. It may be contended 
that this is of limited relevance because any actor involved in nanotechnology works 
within multidisciplinary teams. However with a view to openness and accountability to 
the „outside world‟ better readability of patents is relevant and requiring that an individual 
be able to read and understand a patent does not seem to be a too exaggerated 
demand. Therefore, I tend to think that the imaginary individual partaking in the team 
should be chosen as being somewhat less qualified than the person skilled in the art 
relevant for monodisciplinary inventions. This will force somewhat more elaborate 
disclosures in interdisciplinary inventions.  
Another way to get „better‟ disclosures would be to decouple the inventiveness-
person- skilled-in-the-art from the sufficient-disclosure-person-skilled-in-the-art. This 
would be a more principled intervention in patent law that would require further research 
and for the time being nanotechnology does not present us with the necessity to do so.2 
Defining the person skilled in the art as a team and backing this up by making real life 
interdisciplinary teams, comes quite some way in resolving a possible technology 
shopping problem. A team of examiners is harder to fool than an individual examiner. At 
the same time, it must be admitted that a multidisciplinary team of examiners does not 
solve all problems. After all, it is still unclear how to determine the default discipline of an 
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invention, or, to say it in other words, what standards to use when examining nanotech 
patents.  
3.2 Novelty and inventive step 
As a new technological field, there is relatively little prior art and even less prior 
art explicitly relating to nanotechnology (Zekos 2006, p.366). A small reservoir of prior 
art may have the effect of lowering the actual novelty threshold, because novelty is easy 
to establish. Possibly, this gives rise to broad patents because the formulation of the 
claims does not have to steer clear from much prior art. The issue of the broadness of 
nanotechnology patents gains extra weight in view of the fact that nanotechnology is in 
its formative stages of development. The progress made in this stage may yield building 
blocks on which many later applications will be founded. On the one hand, the 
broadness of patents now granted may affect follow-on innovators negatively. On the 
other hand, broad patents may be necessary to recoup the large investment needed for 
developing laboratory findings into marketable products (Lemley 2005, p.628-629). 
Whether broad patents in nanotechnology are at the moment a good or a bad thing is 
open for discussion. Nevertheless, there can be little discussion that overbroad patents 
that should not have been granted in the first place must be avoided. An adequate 
determination of the state-of-the-art is central to the quality of granted patents. Although 
it is the patent applicant that must indicate what the nearest state-of-the-art is, it is up to 
the patent office to detect any deficiencies. This may be an extra heavy burden in the 
case of nanotechnology, since it is an emergent technology and patent offices struggle 
to find qualified examiners. The workload of the present examiners is already very high 
(Barraclough 2007 and Krempl 2006). In order to ease their workload, patent offices 
could invest in qualified examiners and in optimising the availability of prior art 
information, such as technical information in academic journals and other non-patent 
information. Another avenue through which progress could be booked is by working on a 
standard terminology and metrology in nanotechnology. This is of course not the task of 
patent offices but that of standard setting organisations, such as ISO and ASTM 
International.  
First standards on nanotech terminology have already been adopted (ISO, 2008, 
ASTM Int‟l 2006) or are in the process of being developed (ASTM Int‟l 2009). ISO 
standard TS 27687:2008 on terminology and definitions for nano-objects was adopted in 
2005 and is the first in a planned series of ISO standards covering terminology and 
definitions for various aspects of nanotechnology. In 2007, the OECD set up a Working 
Party on Nanotechnology. It explicitly addresses the issue of standardisation in 
nanotechnology (OECD 2008). However, the work of standard setting organisations 
often progresses slowly. A technology may not be developed enough to know what 
standards concerning semantics, measurement and testing are needed. This seems to 
be the case with respect to nanotechnology. Terminology in nanotechnology literature is 
extremely dynamic (Hullmann & Frycek 2007a, 396). Obviously, it is desirable for patent 
offices to work with standards that have been set by standard setting organisations 
especially if they are adopted globally. That makes communication with patent 
applicants easier. Internal communication between the various divisions within a patent 
office would benefit as well. It makes it also easier to detect prior art in patent databases 
and other literature sources. It may help in clarifying ambiguities in patent claims, making 
the scope of patents clearer, both for patentees and third parties such as competitors 
and licensees. Given the interest that standards on terminology and metrology represent 
for the patent system it seems to me that an argument could be made for active 
participation of patent offices in standard setting procedures. On the one hand, patent 
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offices have an important role in the patent system as gatekeepers for the patentability 
of nanotechnology inventions. In fulfilling this role they are highly dependent on a 
uniform terminology and metrology in nanotechnology. Differences in terminology and 
metrology can have far reaching implications, ultimately that patents are granted that 
should not have been granted in the first place. Patent offices should therefore make 
sure that their standardisation needs are taken into consideration. On the other hand, 
patent offices being in the unique position they are in see many applications from 
various domains of nanotechnology and thus could deliver an important contribution to 
the standardisation process. In short, there is good reason to have patent offices 
participating in standard setting processes concerning terminology and metrology.  
3.3 Industrial applicability 
In situations of technological change, such as with emerging technologies, there 
is a certain risk that broad patents are being granted on enabling technology. This has 
possibly been the case in biotechnology where patents have been granted on upstream 
research results (Heller & Eisenberg 1998; Zekos 2006a). Theoretically, the requirement 
of industrial applicability could be used as a brake on overbroad, upstream research 
patents which are far removed from a product that could be placed on the market. Given 
their abstract character, they may have no „practical‟ application. In reality, however, the 
EPO hardly uses the industrial applicability requirement for this purpose (EPO 2006, p. 
170-171).  
In the field of biotechnology, it has been tried to use industrial applicability for just 
that purpose. The European Directive on biotechnological inventions Article 5(3) 
Directive 98/44/EC indicates that the industrial application of a sequence or a partial 
sequence of a gene must be disclosed in the patent application. It is not quite clear how 
this provision must be interpreted. One option is to see it as a mere repetition of the 
general patentability requirement of industrial applicability. This interpretation does at 
first seem less likely since it would be non-sensical: it does not add anything to the 
normal application of the requirement of industrial applicability. Another interpretation 
may be that the function of a gene patent should be mentioned in the claims. Then the 
patent only confers an exclusive right to use the gene for the specified function. The 
latter interpretation would make for specific law for gene patents. In 2005, the European 
Commission has evaluated the effect of Article 5(3) of the Directive.3 The Commission 
indicated that (European Commission 2005): 
„as a specific field of technology becomes mature, the application of the normal 
patent criteria of novelty, inventive step and industrial applicability means that 
future patents are necessarily limited in scope because the invention claimed has 
to be distinguished from the vast array of what is already known in the field[11]. 
As it is now seventeen years since a Directive was first proposed, it may be 
questionable whether attempting to further refine the scope of protection of gene 
sequence patents in the light of divergences between national legislations will 
have any significant effect on actors in the field.‟   
The Commission indicates that in a relatively short time this piece of special legislation – 
if at least it is to be interpreted as such - has made itself superfluous. Apparently, 
purpose-bound patents do not give patentees an effective protection. Patents would 
become too narrow. What implications does this have for the desirability of specific rules 
for the industrial applicability of nanotechnology patents? It is likely that also in the case 
of nanotechnology patents the issuing of overbroad patents is a problem associated with 
the initial stages of development of the technology. The lack of scientific knowledge and 
prior art in general makes it difficult to draw a line between broad and overbroad 
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protection. Any attempt at a solution of what seems to be a recurring problem with any 
new technology will be handicapped by the same lack of scientific insight in the nascent 
technology and therefore difficult to implement. The slowly growing scientific insight in 
the technology points in two directions: on the one hand, it points to a solution later in 
the technology life cycle when more is known about the technology and its underlying 
science. On the other hand, it points to more transparency right from the start. Opening 
up possibilities for revocation of an overbroad patent „later on‟ could be an effective 
intervention. Opposition against a „European patent‟ is however limited to just nine 
months after the grant. In this respect, the advent of a centralised European court 
system would bring relief. The development of the legal foundations for a European and 
Community Patent Court has been set in motion (European Commission 2009). Lack of 
industrial applicability can be a ground for invalidating patents later on in a patent‟s life 
cycle, especially if no concrete applications of the patented invention appear. It may 
however not always be easy to determine whether that is the case. For instance where 
patented upstream research results can function as research tools, they still may be said 
to amount to practical applications. This is an argument often raised in biotechnology 
cases. Furthermore, invalidations later in a patent‟s lifecycle do run the risk of lessening 
legal certainty with respect to the validity of granted patents and must therefore be used 
with care. The other option – working on transparency – may therefore be more fruitful. 
As indicated above, ensuring that nanotech patents are sufficiently disclosed is 
important. It is something the courts and the patent office can see to, even without 
special regulation (Burk & Lemley 2003). A change in the definition of the person skilled 
in the art can lead to more encompassing disclosure. Also a change in the standard of 
industrial application – as used by the courts -  may result in more exacting indications of 




According to the European Commission, Europe is not good at transforming 
nanotechnology research into marketable applications (European Commission 2004, 
p.7). Thus, while the numbers show that nanotechnology based patents have not 
reached the high volumes some would have hoped for, patent law is not to blame 
(Kinsler 2006). It offers enough room to patent nanotechnological inventions. The 
possibilities for patenting nanotech inventions should be considered positive.  
At the same time, nanotechnology has a number of characteristics that raise the 
risk of over-patenting, such as patents on building blocks of the technology and 
overlapping patents through inconsistent use of terminology. In this chapter, it is argued 
that such concerns should be addressed. A number of avenues have been identified for 
improving the application of the patent law, specifically as it relates to the inherent 
characteristics of nanotechnology inventions. For instance, a person skilled in the art of 
nanotechnology should be chosen as a team of not too highly qualified workers in the 
partaking technologies so that disclosures of inventions become more exacting. 
Furthermore, patent offices should closely follow work in standardisation of terminology 
and metrology in nanotechnology and if possible they should participate in standard 
setting processes in order to lessen ambiguities that complicate the process of 
patenting. For now, that must result a higher quality of granted patents. At a later stage 
when applications of nanotechnology are being developed and appear on the market, 
ways of facilitating the licensing of nanotechnology will also become a relevant 
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instrument for dealing with innovation in the field of nanotechnology. But that is a future 
concern … 
                                               
1
 The EPO has taken measures to prevent this from happening.  
2
 See T 60/89, OJ 1992, 268, T 694/92, T 187/93 and T 412/93. 
3
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